Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
| ▸ | LPO | P22079 | 4/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.30 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21049622 | 0.86 | FDPS (0.32) | SMN1; SMN2LMNAHPGDHTTKDM4E | |
| SCHEMBL1095619 | 0.83 | FDPS (0.35) | SMN1; SMN2HTTMAPTBLM | |
| SCHEMBL21049572 | 0.82 | MEN1 (0.38) | SMN1; SMN2HTTMAPTCYP1A2BLM | |
| SCHEMBL21049629 | 0.80 | MEN1 (0.41) | SMN1; SMN2HTTMAPTCYP1A2BLM | |
| SCHEMBL21049641 | 0.80 | MEN1 (0.41) | SMN1; SMN2HTTMAPTCYP1A2BLM | |
| SCHEMBL21049626 | 0.80 | MEN1 (0.41) | SMN1; SMN2HTTMAPTCYP1A2BLM | |
| SCHEMBL21049594 | 0.80 | MEN1 (0.41) | SMN1; SMN2HTTMAPTCYP1A2BLM | |
| SCHEMBL22189073 | 0.80 | MEN1 (0.41) | SMN1; SMN2HTTMAPTCYP1A2BLM | |
| SCHEMBL21049536 | 0.80 | MEN1 (0.41) | SMN1; SMN2HTTMAPTCYP1A2BLM | |
| SCHEMBL22189020 | 0.80 | MAPT (0.43) | MAPTCTDSP1LPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559586-B2 | Compositions containing uretdione groups crosslinking at low temperatures | COVESTRO DEUTSCHLAND AG (DE) | 2026-02-24 | — | — | US | claimed |
| EP-4157912-B1 | COMPOSITIONS CONTAINING URETDIONE GROUPS CROSSLINKING AT LOW TEMPERATURES | COVESTRO DEUTSCHLAND AG (DE) | 2024-05-22 | — | — | EP | claimed |
| EP-3997183-B1 | METHOD FOR THE PRODUCTION OF ISOCYANURATES FROM URETDIONES | COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) | 2023-10-04 | — | — | EP | claimed |
| US-20230192941-A1 | COMPOSITIONS CONTAINING URETDIONE GROUPS CROSSLINKING AT LOW TEMPERATURES | COVESTRO DEUTSCHLAND AG (DE) | 2023-06-22 | — | — | US | claimed |
| EP-4157912-A1 | COMPOSITIONS CONTAINING URETDIONE GROUPS CROSSLINKING AT LOW TEMPERATURES | Covestro Deutschland AG (DE) | 2023-04-05 | — | — | EP | claimed |
| US-20220348708-A1 | METHOD FOR PRODUCING ISOCYANURATES FROM URETDIONES | COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) | 2022-11-03 | — | — | US | claimed |
| US-20220251280-A1 | PROCESS OF PREPARING ALLOPHANATE- AND/OR THIOALLOPHANATE GROUP-CONTAINING COMPOUNDS | COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) | 2022-08-11 | — | — | US | claimed |
| EP-3997183-A1 | METHOD FOR PRODUCING ISOCYANURATES FROM URETDIONES | Covestro Intellectual Property GmbH & Co. KG (DE) | 2022-05-18 | — | — | EP | claimed |
| EP-3997141-A1 | PROCESS OF PREPARING ALLOPHANATE- AND/OR THIOALLOPHANATE GROUP-CONTAINING COMPOUNDS | Covestro Intellectual Property GmbH & Co. KG (DE) | 2022-05-18 | — | — | EP | claimed |
| WO-2021239678-A1 | COMPOSITIONS CONTAINING URETDIONE GROUPS CROSSLINKING AT LOW TEMPERATURES | COVESTRO DEUTSCHLAND AG (DE) | 2021-12-02 | — | — | WO | claimed |
| EP-3916032-A1 | COMPOSITIONS CONTAINING URETDIONE GROUPS CROSSLINKING AT LOW TEMPERATURES | Covestro Deutschland AG (DE) | 2021-12-01 | — | — | EP | claimed |
| US-20210009850-A1 | POLYURETHANE POWDER COATING MATERIAL | COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) | 2021-01-14 | — | — | US | claimed |
| WO-2021004980-A1 | PROCESS OF PREPARING ALLOPHANATE- AND/OR THIOALLOPHANATE GROUP-CONTAINING COMPOUNDS | COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) | 2021-01-14 | — | — | WO | claimed |
| WO-2021004978-A1 | METHOD FOR PRODUCING ISOCYANURATES FROM URETDIONES | COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) | 2021-01-14 | — | — | WO | claimed |
| EP-3763792-A1 | METHOD FOR THE PRODUCTION OF ISOCYANURATES FROM URETDIONES | Covestro Deutschland AG (DE) | 2021-01-13 | — | — | EP | claimed |
| EP-3763762-A1 | POLYURETDIONE POWDER VARNISH | Covestro Intellectual Property GmbH & Co. KG (DE) | 2021-01-13 | — | — | EP | claimed |
| US-12559586-B2 | Compositions containing uretdione groups crosslinking at low temperatures | COVESTRO DEUTSCHLAND AG (DE) | 2026-02-24 | — | — | US | disclosed |
| CN-115605525-B | Uretdione-containing compositions that crosslink at low temperatures | 科思创德国股份有限公司 | 2025-01-10 | — | — | CN | disclosed |
| WO-2011141492-A1 | METHODS FOR PRODUCING POLYETHEROLS | BASF SE (DE) | 2011-11-17 | — | — | WO | disclosed |
| US-20110282027-A1 | PROCESS FOR PRODUCING POLYETHEROLS | BASF SE (DE) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559586-B2 | Compositions containing uretdione groups crosslinking at low temperatures | URB2, UQCRB, UQCRC2 | SMN1; SMN2 4159/4885LMNA 1319/4885HPGD 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.